Effects of LDL Receptor Modulation on Lymphatic Function

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Milasan, Andreea ^a,b   Dallaire, François ^b   Mayer, Gaétan ^a,b   Martel, Catherine ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN, MOUSE; PROPROTEIN CONVERTASE 9;

ANIMAL; ATHEROSCLEROSIS; DISEASE MODEL; ENDOTHELIUM CELL; FEMALE; GENETICS; KNOCKOUT MOUSE; LYMPH VESSEL; MALE; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; LYMPHATIC VESSELS; MALE; MICE; MICE, KNOCKOUT; PROPROTEIN CONVERTASE 9; RECEPTORS, LDL;

EID: 84973664661     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27862     Document Type: Article

References (66)

1. Herijgers, N., Van Eck, M., Groot, P. H., Hoogerbrugge, P. M. & Van Berkel, T. J. Low density lipoprotein receptor of macrophages facilitates atherosclerotic lesion formation in C57Bl/6 mice. Arterioscler Thromb Vasc Biol 20, 1961-1967 (2000).
2. Goldstein, J. L. & Brown, M. S. Molecular medicine. The cholesterol quartet. Science 292, 1310-1312 (2001).
3. Linton, M. F., Babaev, V. R., Gleaves, L. A. & Fazio, S. A direct role for the macrophage low density lipoprotein receptor in atherosclerotic lesion formation. J Biol Chem 274, 19204-19210 (1999).
4. Go, G. W. & Mani, A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med 85, 19-28 (2012).
5. Horton, J. D., Cohen, J. C. & Hobbs, H. H. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32, 71-77, doi: 10.1016/j.tibs.2006.12.008 (2007).
6. Poirier, S. & Mayer, G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug design, development and therapy 7, 1135-1148, doi: 10.2147/DDDT.S36984 (2013).
7. Sun, H. et al. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 32, 1585-1595, doi: 10.1161/ATVBAHA. 112.250043 (2012).
8. Lambert, G. et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 147, 4985-4995, doi: 10.1210/en.2006-0098 (2006).
9. Zhao, Z. et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79, 514-523, doi: 10.1086/507488 (2006).
10. Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. The New England journal of medicine 354, 1264-1272, doi: 10.1056/NEJMoa054013 (2006).
11. Soutar, A. K. & Naoumova, R. P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nature clinical practice. Cardiovascular medicine 4, 214-225, doi: 10.1038/ncpcardio0836 (2007).
12. Rader, D. J., Cohen, J. & Hobbs, H. H. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 111, 1795-1803, doi: 10.1172/JCI18925 (2003).
13. Glomset, J. A. The plasma lecithins:cholesterol acyltransferase reaction. Journal of lipid research 9, 155-167 (1968).
14. Temel, R. E. & Brown, J. M. Biliary and nonbiliary contributions to reverse cholesterol transport. Curr Opin Lipidol 23, 85-90, doi: 10.1097/MOL.0b013e3283508c21 (2012).
15. Zhang, H., Temel, R. E. & Martel, C. Cholesterol and lipoprotein metabolism: Early Career Committee contribution. Arterioscler Thromb Vasc Biol 34, 1791-1794, doi: 10.1161/ATVBAHA.114.304267 (2014).
16. Investigators, A.-H. et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine 365, 2255-2267, doi: 10.1056/NEJMoa1107579 (2011).
17. Schwartz, G. G. et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 158, 896-901 e893, doi: 10.1016/j.ahj.2009.09.017 (2009).
18. Tardif, J. C. et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 35, 3277-3286, doi: 10.1093/eurheartj/ehu171 (2014).
19. Everett, B. M., Smith, R. J. & Hiatt, W. R. Reducing LDL with PCSK9 Inhibitors- The Clinical Benefit of Lipid Drugs. N Engl J Med 373, 1588-1591, doi: 10.1056/NEJMp1508120 (2015).
20. Giunzioni, I. et al. Local Effects of Human PCSK9 on the Atherosclerotic Lesion. The Journal of pathology, doi: 10.1002/path.4630 (2015).
21. Langhi, C. et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochemical and biophysical research communications 390, 1288-1293, doi: 10.1016/j.bbrc.2009.10.138 (2009).
22. Schmidt, R. J. et al. A novel splicing variant of proprotein convertase subtilisin/kexin type 9. DNA and cell biology 27, 183-189, doi: 10.1089/dna.2007.0667 (2008).
23. Ferri, N. et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 220, 381-386, doi: 10.1016/j.atherosclerosis.2011.11.026 (2012).
24. Martel, C. et al. Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest 123, 1571-1579, doi: 10.1172/JCI63685 (2013).
25. Martel, C. & Randolph, G. J. Atherosclerosis and transit of HDL through the lymphatic vasculature. Current atherosclerosis reports 15, 354, doi: 10.1007/s11883-013-0354-4 (2013).
26. Milasan, A., Ledoux, J. & Martel, C. Lymphatic network in atherosclerosis: the underestimated path. Future Science OA 1, 1-10, doi: 10.4155/fso.15.61 (2015).
27. Tammela, T. & Alitalo, K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 140, 460-476, doi: 10.1016/j. cell.2010.01.045 (2010).
28. Jeltsch, M. et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276, 1423-1425 (1997).
29. Baluk, P. et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med 204, 2349-2362, doi: 10.1084/jem.20062596 (2007).
30. von der Weid, P. Y. & Zawieja, D. C. Lymphatic smooth muscle: the motor unit of lymph drainage. Int J Biochem Cell Biol 36, 1147-1153, doi: 10.1016/j.biocel.2003.12.008 (2004).
31. Breslin, J. W. et al. Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism. Am J Physiol Heart Circ Physiol 293, H709-718, doi: 10.1152/ajpheart.00102.2007 (2007).
32. Davis, M. J., Lane, M. M., Scallan, J. P., Gashev, A. A. & Zawieja, D. C. An automated method to control preload by compensation for stress relaxation in spontaneously contracting, isometric rat mesenteric lymphatics. Microcirculation 14, 603-612, doi: 10.1080/10739680701436152 (2007).
33. Goukassian, D. A. et al. Engineering the response to vascular injury: divergent effects of deregulated E2F1 expression on vascular smooth muscle cells and endothelial cells result in endothelial recovery and inhibition of neointimal growth. Circ Res 93, 162-169, doi: 10.1161/01.RES.0000082980.94211.3A (2003).
34. Joukov, V. et al. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem 273, 6599-6602 (1998).
35. von der Weid, P. Y., Lee, S., Imtiaz, M. S., Zawieja, D. C. & Davis, M. J. Electrophysiological properties of rat mesenteric lymphatic vessels and their regulation by stretch. Lymphat Res Biol 12, 66-75, doi: 10.1089/lrb.2013.0045 (2014).
36. D'Alessio, S. et al. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest 124, 3863-3878, doi: 10.1172/JCI72189 (2014).
37. Llodra, J. et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proceedings of the National Academy of Sciences of the United States of America 101, 11779-11784, doi: 10.1073/pnas.0403259101 (2004).
38. Johnson, R. A. Lymphatics of blood vessels. Lymphology 2, 44-56 (1969).
39. Xu, X., Lin, H., Lv, H., Zhang, M. & Zhang, Y. Adventitial lymphatic vessels-an important role in atherosclerosis. Med Hypotheses 69, 1238-1241, doi: 10.1016/j.mehy.2007.04.007 (2007).
40. Drozdz, K. et al. Adventitial lymphatics and atherosclerosis. Lymphology 45, 26-33 (2012).
41. Vuorio, T. et al. Lymphatic vessel insufficiency in hypercholesterolemic mice alters lipoprotein levels and promotes atherogenesis. Arterioscler Thromb Vasc Biol 34, 1162-1170, doi: 10.1161/ATVBAHA.114.302528 (2014).
42. Kutkut, I., Meens, M. J., McKee, T. A., Bochaton-Piallat, M. L. & Kwak, B. R. Lymphatic vessels: an emerging actor in atherosclerotic plaque development. Eur J Clin Invest 45, 100-108, doi: 10.1111/eci.12372 (2015).
43. Denis, M. et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 125, 894-901, doi: 10.1161/CIRCULATIONAHA.111.057406 (2012).
44. Weiler, M. & Dixon, J. B. Differential transport function of lymphatic vessels in the rat tail model and the long-term effects of Indocyanine Green as assessed with near-infrared imaging. Front Physiol 4, 215, doi: 10.3389/fphys.2013.00215 (2013).
45. Angeli, V. et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21, 561-574, doi: 10.1016/j.immuni.2004.09.003 (2004).
46. Rashid, S. et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proceedings of the National Academy of Sciences of the United States of America 102, 5374-5379, doi: 10.1073/pnas.0501652102 (2005).
47. Lim, H. Y. et al. Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and degeneration. Am J Pathol 175, 1328-1337, doi: 10.2353/ajpath.2009.080963 (2009).
48. Bolduc, V. et al. Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice. American journal of physiology. Heart and circulatory physiology 301, H2081-2092, doi: 10.1152/ajpheart.00706.2011 (2011).
49. Gendron, M. E. et al. Late chronic catechin antioxidant treatment is deleterious to the endothelial function in aging mice with established atherosclerosis. Am J Physiol Heart Circ Physiol 298, H2062-2070, doi: 10.1152/ajpheart.00532.2009 (2010).
50. Drouin, A. et al. Catechin treatment improves cerebrovascular flow-mediated dilation and learning abilities in atherosclerotic mice. Am J Physiol Heart Circ Physiol 300, H1032-1043, doi: 10.1152/ajpheart.00410.2010 (2011).
51. Laurila, A. et al. High-fat, high-cholesterol diet increases the incidence of gastritis in LDL receptor-negative mice. Arterioscler Thromb Vasc Biol 21, 991-996 (2001).
52. Hasty, A. H. et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 276, 37402-37408, doi: 10.1074/jbc.M010176200 (2001).
53. Zolla, V. et al. Aging-related anatomical and biochemical changes in lymphatic collectors impair lymph transport, fluid homeostasis, and pathogen clearance. Aging cell 14, 582-594, doi: 10.1111/acel.12330 (2015).
54. Castelli, W. P. et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 55, 767-772 (1977).
55. Roubtsova, A. et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 31, 785-791, doi: 10.1161/ATVBAHA.110.220988 (2011).
56. Demers, A. et al. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver. Arterioscler Thromb Vasc Biol, doi: 10.1161/ATVBAHA.115.306032 (2015).
57. Le May, C. et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 29, 684-690, doi: 10.1161/ATVBAHA.108.181586 (2009).
58. Farhat, N. et al. Angiopoietin-like 2 promotes atherogenesis in mice. J Am Heart Assoc 2, e000201, doi: 10.1161/JAHA.113.000201 (2013).
59. Cohen, R. A. et al. Mechanism of nitric oxide-induced vasodilatation: refilling of intracellular stores by sarcoplasmic reticulum Ca2+ ATPase and inhibition of store-operated Ca2+ influx. Circ Res 84, 210-219 (1999).
60. Saaristo, A. et al. Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 18, 1707-1709, doi: 10.1096/fj.04-1592fje (2004).
61. Wu, H. M., Huang, Q., Yuan, Y. & Granger, H. J. VEGF induces NO-dependent hyperpermeability in coronary venules. The American journal of physiology 271, H2735-2739 (1996).
62. Mayhan, W. G. VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway. The American journal of physiology 276, C1148-1153 (1999).
63. Aramoto, H., Breslin, J. W., Pappas, P. J., Hobson, R. W., 2nd & Duran, W. N. Vascular endothelial growth factor stimulates differential signaling pathways in in vivo microcirculation. American journal of physiology. Heart and circulatory physiology 287, H1590-1598, doi: 10.1152/ajpheart.00767.2003 (2004).
64. Scallan, J. P., Hill, M. A. & Davis, M. J. Lymphatic vascular integrity is disrupted in type 2 diabetes due to impaired nitric oxide signalling. Cardiovasc Res 107, 89-97, doi: 10.1093/cvr/cvv117 (2015).
65. Randolph, G. J., Angeli, V. & Swartz, M. A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 5, 617-628, doi: 10.1038/nri1670 (2005).
66. Platt, A. M. et al. Normal dendritic cell mobilization to lymph nodes under conditions of severe lymphatic hypoplasia. J Immunol 190, 4608-4620, doi: 10.4049/jimmunol.1202600 (2013).